Evidence backs surgery for BRCA1/2 women:
This article was originally published in Clinica
Executive Summary
Women with mutations in their BRCA1 and BRCA2 genes may be three times less likely to develop breast or ovarian cancer if they undergo surgery. In a prospective study of 170 patients, researchers found that the removal of the ovaries and fallopian tubes, or oophorectomy, was associated with a 75% decreased risk of subsequent breast or ovarian cancer. The study, by researchers from the Memorial Sloan-Kettering Cancer Center, in New York, appears in The New England Journal of Medicine (May 23).
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.